Latest Distribution Partnerships News

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

BauMart Holdings has unveiled a multi-pronged strategy to tackle construction labour shortages, advance green building materials, and expand mining equipment services, supported by a $482,000 rights issue.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Yowie Group’s Q2 FY25 results reveal a mixed performance with a 33% revenue drop in North America offset by growth in Australia and ongoing cost optimisation efforts.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Pure Hydrogen advances its zero-emission vehicle strategy with key deliveries, US partnerships, and a planned demerger of its natural gas assets into Eastern Gas Limited.

Volt Group Limited reported a robust 20% increase in FY24 revenue receipts, driven by strong EcoQuip growth and strategic contract wins, while advancing its zero-emission ATEN technology with promising trials underway.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.

Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.